> Detailanzeige

Stähli, Barbara E; Nozza, Anna; Schrieks, Ilse C; Buse, John B; Malmberg, Klas; Mellbin, Linda; Neal, Bruce; Nicholls, Stephen J; Rydén, Lars; Svensson, Anders; Wedel, Hans; Weichert, Arlette; Lincoff, A Michael; Grobbee, Diederick E; Tardif, Jean-Claude; Schwartz, Gregory G

Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome
  • Beteiligte: Stähli, Barbara E; Nozza, Anna; Schrieks, Ilse C; Buse, John B; Malmberg, Klas; Mellbin, Linda; Neal, Bruce; Nicholls, Stephen J; Rydén, Lars; Svensson, Anders; Wedel, Hans; Weichert, Arlette; Lincoff, A Michael; Grobbee, Diederick E; Tardif, Jean-Claude; Schwartz, Gregory G
  • Erschienen: The Endocrine Society, 2018
  • Erschienen in: The Journal of Clinical Endocrinology & Metabolism
  • Sprache: Englisch
  • DOI: 10.1210/jc.2017-02772
  • ISSN: 0021-972X; 1945-7197
  • Schlagwörter: Biochemistry (medical) ; Clinical Biochemistry ; Endocrinology ; Biochemistry ; Endocrinology, Diabetes and Metabolism
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Objective</jats:title> <jats:p>Insulin resistance has been linked to development and progression of atherosclerosis and is present in most patients with type 2 diabetes. Whether the degree of insulin resistance predicts adverse outcomes in patients with type 2 diabetes and acute coronary syndrome (ACS) is uncertain.</jats:p> </jats:sec> <jats:sec> <jats:title>Design</jats:title> <jats:p>The Effect of Aleglitazar on Cardiovascular Outcomes after Acute Coronary Syndrome in Patients with Type 2 Diabetes Mellitus trial compared the peroxisome proliferator-activated receptor-α/γ agonist aleglitazar with placebo in patients with type 2 diabetes and recent ACS. In participants not treated with insulin, we determined whether baseline homeostasis model assessment of insulin resistance (HOMA-IR; n = 4303) or the change in HOMA-IR on assigned study treatment (n = 3568) was related to the risk of death or major adverse cardiovascular events (cardiovascular death, myocardial infarction, and stroke) in unadjusted and adjusted models. Because an inverse association of HOMA-IR with N-terminal pro-B-type natriuretic peptide (NT-proBNP) has been described, we specifically examined effects of adjustment for the latter.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>In unadjusted analysis, twofold higher baseline HOMA-IR was associated with lower risk of death [hazard ratio (HR): 0.79, 95% CI: 0.68 to 0.91, P = 0.002]. Adjustment for 24 standard demographic and clinical variables had minimal effect on this association. However, after further adjustment for NT-proBNP, the association of HOMA-IR with death was no longer present (adjusted HR: 0.99, 95% CI: 0.83 to 1.19, P = 0.94). Baseline HOMA-IR was not associated with major adverse cardiovascular events, nor was the change in HOMA-IR on study treatment associated with death or major adverse cardiovascular events.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>After accounting for levels of NT-proBNP, insulin resistance assessed by HOMA-IR is not related to the risk of death or major adverse cardiovascular events in patients with type 2 diabetes and ACS.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang